Obesity decreases the population of CD4+ T cells which play a critical role in NAFLD-HCC progression and loss of hepatic CD4+ T cells compromises immunotherapies, such as RNA vaccine (M30) and anti-OX40 antibody-mediated therapy against tumor cell growth in the liver (101, 102). Here, CD4 is linked to metabolic dysfunction-associated steatotic liver disease.